Delving into the Latest Updates on Shenzhou Cell Engineering Co. Ltd. with Synapse

Overview

Basic Info

Introduction

Shenzhou Cell Engineering Co Ltd. is an innovative biopharmaceutical and vaccine research and development company. It has established a complete set of upstream and downstream technology platforms for biopharmaceuticals and vaccines, and independently developed a rich product pipeline that covers numerous fields including malignant tumors, autoimmune diseases, genetic diseases, and disease prevention.

Tags

Neoplasms

Immune System Diseases

Skin and Musculoskeletal Diseases

Monoclonal antibody

Therapeutic vaccine

Multivalent vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	6
Neoplasms	5
Hemic and Lymphatic Diseases	4
Immune System Diseases	4
Nervous System Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	4
Prophylactic vaccine	3
Biological products	1
Recombinant coagulation factor	1
Fab fragment	1

Top 5 Target	Count

SARS-CoV-2 S protein	3
VEGF-A(Vascular endothelial growth factor A)	1
PD-1(Programmed cell death protein 1)	1
CD38(Lymphocyte differentiation antigen CD38)	1
TNF-α(Tumor necrosis factor α)	1

(1) Ia期主要目的：评估SCT520FF单次给药安全耐受性，确定最大耐受剂量（MTD）。次要目的：评估SCT520FF单次给药初步疗效；评估SCT520FF单次给药PK、PD特征；评估SCT520FF免疫原性。 (2) Ib期主要目的：评估SCT520FF多次给药安全耐受性，确定MTD。次要目的：评估SCT520FF多次给药初步疗效；评估SCT520FF多次给药PK、PD特征；评估SCT520FF免疫原性。

[Translation]

(1) Phase Ia Primary purpose: To evaluate the safety and tolerability of a single dose of SCT520FF and determine the maximum tolerated dose (MTD). Secondary purpose: To evaluate the preliminary efficacy of a single dose of SCT520FF; To evaluate the PK and PD characteristics of a single dose of SCT520FF; To evaluate the immunogenicity of SCT520FF. (2) Phase Ib Primary purpose: To evaluate the safety and tolerability of multiple doses of SCT520FF and determine the MTD. Secondary purpose: To evaluate the preliminary efficacy of multiple doses of SCT520FF; To evaluate the PK and PD characteristics of multiple doses of SCT520FF; To evaluate the immunogenicity of SCT520FF.

Start Date22 Nov 2024

Sponsor / Collaborator

Shenzhou Cell Engineering Co. Ltd.

CTR20243305

/ RecruitingPhase 1/2

一项评估SCTB41用于治疗晚期恶性实体瘤患者的安全耐受性、药代动力学和抗肿瘤活性的开放、多中心、剂量递增和剂量扩展的I/Ⅱ期临床试验

[Translation] An open-label, multicenter, dose-escalation and dose-expansion Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of SCTB41 in the treatment of patients with advanced malignant solid tumors

Ia期：主要评估SCTB41单药在晚期恶性实体瘤患者中的安全性和耐受性。 Ib期：确定SCTB41单药在晚期恶性实体瘤患者中的II期推荐剂量（RP2D）并评估初步抗肿瘤活性及安全性。 Ⅱ期：评估SCTB41单药在晚期恶性实体瘤（特定瘤种）患者中的初步疗效。

[Translation]

Phase Ia: Mainly evaluate the safety and tolerability of SCTB41 monotherapy in patients with advanced malignant solid tumors. Phase Ib: Determine the Phase II recommended dose (RP2D) of SCTB41 monotherapy in patients with advanced malignant solid tumors and evaluate the preliminary anti-tumor activity and safety. Phase II: Evaluate the preliminary efficacy of SCTB41 monotherapy in patients with advanced malignant solid tumors (specific tumor types).

Start Date25 Sep 2024

Sponsor / Collaborator

Shenzhou Cell Engineering Co. Ltd.

CTR20243047

/ RecruitingPhase 2

一项评价SCT650C在中轴型脊柱关节炎患者中的安全性和有效性的随机、双盲、安慰剂对照的II期临床试验

[Translation] A randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of SCT650C in patients with axial spondyloarthritis

评估SCT650C在中轴型脊柱关节炎受试者中的安全性和有效性。

[Translation]

To evaluate the safety and efficacy of SCT650C in subjects with axial spondyloarthritis.

Start Date20 Aug 2024

Sponsor / Collaborator

Shenzhou Cell Engineering Co. Ltd.

100 Clinical Results associated with Shenzhou Cell Engineering Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhou Cell Engineering Co. Ltd.

Login to view more data

100 Deals associated with Shenzhou Cell Engineering Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhou Cell Engineering Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

1

IND Application

IND Approval

2

Phase 1

Phase 2

2

Phase 3

Approved

2

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Adalimumab biosimilar (Sinocelltech Group) ( TNF-α )	Crohn Disease More	Approved
Finotonlimab ( PD-1 )	Hepatocellular Carcinoma More	NDA/BLA
Recombinant 14 valent Human Papillomavirus Vaccine14 valent HPV vaccine(Sinocelltech)	Vulvar Neoplasms More	Phase 3
Recombinant coagulation factor VIII ( Sino Cell Technologies) ( F10 )	Hemorrhage More	Phase 3
Turenkibart ( IL-17A )	Ankylosing Spondylitis More	Phase 2